Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.

He DK, Wang L, Qin J, Zhang S, Lu W, Li L, Zhang JM, Bao WQ, Song XQ, Liu HT.

Acta Pharmacol Sin. 2012 Nov;33(11):1417-23. doi: 10.1038/aps.2012.118. Epub 2012 Oct 29.

2.

[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].

Zhang S, Wang L, Lu W.

Zhongguo Dang Dai Er Ke Za Zhi. 2008 Apr;10(2):105-9. Chinese.

PMID:
18433522
3.

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.

Peng J, Zhang HN, Liu ZS, Xu H, Wang Y.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):684-92. doi: 10.5414/CP202078.

PMID:
24887335
4.

Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.

Zhang ZB, Ji SM, Han Y, Zang LL, Wang YH, Lu W, Wang L, Wu Y.

Eur J Clin Pharmacol. 2017 Apr;73(4):445-453. doi: 10.1007/s00228-016-2190-2. Epub 2017 Jan 7.

PMID:
28064355
5.

Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.

Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Domínguez-Gil A, García MJ.

Ther Drug Monit. 2008 Aug;30(4):483-9. doi: 10.1097/FTD.0b013e31817fd4d4.

PMID:
18641550
6.

Population pharmacokinetics of valproate in Chinese children with epilepsy.

Jiang DC, Wang L, Wang YQ, Li L, Lu W, Bai XR.

Acta Pharmacol Sin. 2007 Oct;28(10):1677-84.

7.

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A.

Epilepsy Res. 2000 Nov;42(1):23-31.

PMID:
10996503
8.

Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.

Lalic M, Cvejic J, Popovic J, Bozic K, Golocorbin-Kon S, Al-Salami H, Mikov M.

Eur J Drug Metab Pharmacokinet. 2009 Apr-Jun;34(2):93-9.

PMID:
19645218
9.

Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.

Wang YH, Wang L, Lu W, Shang DW, Wei MJ, Wu Y.

Acta Pharmacol Sin. 2012 Jun;33(6):845-51. doi: 10.1038/aps.2012.57.

10.

Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.

Brzaković B, Vučićević K, Kovačević SV, Miljković B, Prostran M, Martinović Ž, Pokrajac M.

Eur J Clin Pharmacol. 2014 Feb;70(2):179-85. doi: 10.1007/s00228-013-1606-5. Epub 2013 Nov 19.

PMID:
24240511
11.

The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.

Takeuchi T, Natsume J, Kidokoro H, Ishihara N, Yamamoto H, Azuma Y, Ito Y, Kurahashi N, Tsuji T, Suzuki M, Itomi K, Yamada K, Kurahashi H, Abe S, Okumura A, Maruyama K, Negoro T, Watanabe K, Kojima S.

Brain Dev. 2016 Sep;38(8):723-30. doi: 10.1016/j.braindev.2016.03.004. Epub 2016 Mar 28.

PMID:
27033151
12.

Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.

Yu Y, Zhang Q, Xu W, Lv C, Hao G.

Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):345-51. doi: 10.1007/s13318-015-0266-5. Epub 2015 Feb 21. Erratum in: Eur J Drug Metab Pharmacokinet. 2016 Oct 14;:. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):171.

PMID:
25700977
13.

Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.

Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC.

Br J Clin Pharmacol. 1998 Dec;46(6):547-51.

14.

Effect of oral contraceptives on lamotrigine levels depends on comedication.

Wegner I, Wilhelm AJ, Lambrechts DA, Sander JW, Lindhout D.

Acta Neurol Scand. 2014 Jun;129(6):393-8. doi: 10.1111/ane.12197. Epub 2013 Nov 8.

PMID:
24571554
15.

Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K.

Eur J Clin Pharmacol. 2016 May;72(5):555-62. doi: 10.1007/s00228-016-2008-2. Epub 2016 Jan 20.

PMID:
26790665
16.

Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.

Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y.

Eur J Clin Pharmacol. 2015 Nov;71(11):1341-7. doi: 10.1007/s00228-015-1925-9. Epub 2015 Aug 26.

PMID:
26303110
17.

An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy.

Baldoni AO, Freitas-Lima P, de Santi Ferreira FI, Martinez EZ, Queiroz RH, Sakamoto AC, Alexandre V, Perucca E, Pereira LR.

Clin Exp Pharmacol Physiol. 2016 Jul;43(7):685-9. doi: 10.1111/1440-1681.12584.

PMID:
27120710
18.

Saliva and serum concentration of lamotrigine in patients with epilepsy.

Tsiropoulos I, Kristensen O, Klitgaard NA.

Ther Drug Monit. 2000 Oct;22(5):517-21.

PMID:
11034255
19.

Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.

Eriksson AS, Hoppu K, Nergårdh A, Boreus L.

Epilepsia. 1996 Aug;37(8):769-73.

PMID:
8764817
20.

Population pharmacokinetics of lamotrigine in Indian epileptic patients.

Mallaysamy S, Johnson MG, Rao PG, Rajakannan T, Bathala L, Arumugam K, van Hasselt JG, Ramakrishna D.

Eur J Clin Pharmacol. 2013 Jan;69(1):43-52. doi: 10.1007/s00228-012-1311-9. Epub 2012 Jun 2.

PMID:
22660444

Supplemental Content

Support Center